Citations (89)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Margaret Bohmer, Yonger Xue, Katarina Jankovic & Yizhou Dong. (2023) Advances in engineering and delivery strategies for cytokine immunotherapy. Expert Opinion on Drug Delivery 20:5, pages 579-595.
Read now
Read now
Kensuke Matsuda, Jo Taisuke, Masashi Miyauchi, Kazuhiro Toyama, Kumi Nakazaki, Hiroki Matsui, Kiyohide Fushimi, Hideo Yasunaga & Mineo Kurokawa. (2020) Primary prophylaxis with pegfilgrastim in patients with newly-diagnosed diffuse large B-cell lymphoma: propensity score and instrumental variable analyses. Leukemia & Lymphoma 61:10, pages 2435-2441.
Read now
Read now
Ali McBride, Kim Campbell, Mohan Bikkina, Karen MacDonald, Ivo Abraham & Sanjeev Balu. (2018) Reply: Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia. Journal of Medical Economics 21:6, pages 606-609.
Read now
Read now
Margherita Ratti & Gianluca Tomasello. (2015) Lipegfilgrastim for the prophylaxis and treatment of chemotherapy-induced neutropenia. Expert Review of Clinical Pharmacology 8:1, pages 15-24.
Read now
Read now
Markus Scholz, Manuela Ackermann, Frank Emmrich, Markus Loeffler & Manja Kamprad. (2009) Effectiveness of cytopenia prophylaxis for different filgrastim and pegfilgrastim schedules in a chemotherapy mouse model. Biologics: Targets and Therapy 3, pages 27-37.
Read now
Read now
Gary Lyman, Anjana Lalla, Richard Barron & Robert W. Dubois. (2009) Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States. Current Medical Research and Opinion 25:2, pages 401-411.
Read now
Read now
A. Engert, L. Griskevicius, Y. Zyuzgin, H. Lubenau & A. del Giglio. (2009) XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy. Leukemia & Lymphoma 50:3, pages 374-379.
Read now
Read now
Mariko Morishita & Robert C Leonard. (2008) Pegfilgrastim; a neutrophil mediated granulocyte colony stimulating factor–expanding uses in cancer chemotherapy. Expert Opinion on Biological Therapy 8:7, pages 993-1001.
Read now
Read now
Steven W. Lane, Julie Crawford, Melita Kenealy, Gavin Cull, John F. Seymour, H. Miles Prince, Paula Marlton, Devinder Gill & Peter N. Mollee. (2006) Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF) supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancy. Leukemia & Lymphoma 47:9, pages 1813-1817.
Read now
Read now
Gary H Lyman. (2005) Pegfilgrastim: a granulocyte colony-stimulating factor with sustained duration of action. Expert Opinion on Biological Therapy 5:12, pages 1635-1646.
Read now
Read now
Raymond Ng & Michael D Green. (2005) Pegfilgrastim: evidence in support of its use with cytotoxic chemotherapy. Expert Review of Anticancer Therapy 5:4, pages 585-590.
Read now
Read now
Articles from other publishers (78)
Yasutaka Masuda, Takashi Oyama, Kumi Nakazaki, Yudai Nakai, Ken Sasaki, Kensuke Matsuda, Yosuke Masamoto & Mineo Kurokawa. (2023) Aortitis Associated with Prophylactic Short-acting Granulocyte Colony-stimulating Factor Administration: A Case Report and Review of the Literature. Internal Medicine 62:11, pages 1647-1652.
Crossref
Crossref
Claudio Cerchione, Davide Nappi, Alessandra Romano & Giovanni Martinelli. (2022) Pegfilgrastim in Supportive Care of Hodgkin Lymphoma. Cancers 14:17, pages 4063.
Crossref
Crossref
Shruti Rastogi, Vivekanandan Kalaiselvan, Yousef A. Bin Jardan, Saima Zameer & Maryam Sarwat. (2022) Comparative Study of Adverse Drug Reactions Associated with Filgrastim and Pegfilgrastim Using the EudraVigilance Database. Biology 11:2, pages 340.
Crossref
Crossref
Fatemeh Yadavar Nikravesh, Samira Shirkhani, Elham Bayat, Yeganeh Talebkhan, Esmat Mirabzadeh, Masoumeh Sabzalinejad, Hooman Aghamirza Moghim Aliabadi, Leila Nematollahi, Yalda Hosseinzadeh Ardakani & Soroush Sardari. (2022) Extension of human GCSF serum half-life by the fusion of albumin binding domain. Scientific Reports 12:1.
Crossref
Crossref
Xiang Ji, Lisheng Xu, Pengfei Pan, Zhiyun Xu, Aihua Wang & Yu Li. (2021) Efficacy and safety of 3 mg pegylated recombinant human granulocyte colony‐stimulating factor as support to chemotherapy for lung cancer. Thoracic Cancer 13:1, pages 117-125.
Crossref
Crossref
Shruti Rastogi, Vivekananda Kalaiselvan, Sher Ali, Ajaz Ahmad, Sameer Ahmad Guru & Maryam Sarwat. (2021) Efficacy and Safety of Filgrastim and Its Biosimilars to Prevent Febrile Neutropenia in Cancer Patients: A Prospective Study and Meta-Analysis. Biology 10:10, pages 1069.
Crossref
Crossref
Patrick R Tilleul, Barry S Rodgers-Gray & James O Edwards. (2020) Introduction of biosimilar pegfilgrastim in France: Economic analysis of switching from originator. Journal of Oncology Pharmacy Practice 27:7, pages 1604-1615.
Crossref
Crossref
Kensuke Matsuda, Masataka Ise, Arika Shimura, Akira Honda, Yosuke Masamoto, Taisuke Jo, Hideo Yasunaga & Mineo Kurokawa. (2021) Use of wide-spectrum antimicrobials with blood culture tests during chemotherapy as an accurate marker of febrile neutropenia in the DPC database: A validation study. Journal of Infection and Chemotherapy 27:10, pages 1541-1542.
Crossref
Crossref
Kensuke Matsuda, Taisuke Jo, Masashi Miyauchi, Kazuhiro Toyama, Kumi Nakazaki, Hiroki Matsui, Kiyohide Fushimi, Hideo Yasunaga & Mineo Kurokawa. (2021) Difference of preventing effects of G-CSF according to age in patients with malignant lymphoma: A nation-wide analysis in Japan. Journal of Infection and Chemotherapy 27:8, pages 1151-1155.
Crossref
Crossref
Masataka Ise, Kensuke Matsuda, Arika Shimura, Yosuke Masamoto & Mineo Kurokawa. (2021) Primary prophylaxis with pegfilgrastim during the first cycle of R-CHOP to avoid reduction of dose intensity in elderly patients. International Journal of Hematology 113:6, pages 823-831.
Crossref
Crossref
Hartmut Link, G. Illerhaus, U. M. Martens, A. Salar, R. Depenbusch, A. Köhler, M. Engelhardt, S. Mahlmann, M. Zaiss, A. Lammerich, P. Bias & A. Buchner. (2020) Efficacy and safety of lipegfilgrastim versus pegfilgrastim in elderly patients with aggressive B cell non-Hodgkin lymphoma (B-NHL): results of the randomized, open-label, non-inferiority AVOID neutropenia study. Supportive Care in Cancer 29:5, pages 2519-2527.
Crossref
Crossref
Ken Sasaki, Kensuke Matsuda, Masashi Miyauchi, Akira Honda, Arika Shimura, Yosuke Masamoto & Mineo Kurokawa. (2021) A retrospective analysis on arteritis after administration of granulocyte colony-stimulating factor. Annals of Hematology 100:5, pages 1341-1343.
Crossref
Crossref
Yusuke Kitagawa, Hiroki Osumi, Eiji Shinozaki, Yumiko Ota, Izuma Nakayama, Takeshi Suzuki, Takeru Wakatsuki, Mariko Ogura, Akira Ooki, Daisuke Takahari, Mitsukuni Suenaga, Keisho Chin & Kensei Yamaguchi. (2020) Clinical utility of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing severe neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab: a single-center retrospective study. BMC Cancer 20:1.
Crossref
Crossref
Mahsa Mohseni, Morteza Arab-Zozani, Ayat Ahmadi, Babak Salimi & Ali Akbari Sari. (2020) Meta-analysis of Pegfilgrastim over Filgrastim in the Treatment of Chemotherapy-induced Neutropenia. Annals of Cancer Research and Therapy 28:2, pages 71-80.
Crossref
Crossref
Paul Cornes, Pere Gascon, Arnold G. Vulto & Matti Aapro. (2020) Biosimilar Pegfilgrastim: Improving Access and Optimising Practice to Supportive Care that Enables Cure. BioDrugs 34:3, pages 255-263.
Crossref
Crossref
Yong Wang, Lin Chen, Fen Liu, Ning Zhao, Liyao Xu, Biqi Fu & Yong Li. (2019) Efficacy and tolerability of granulocyte colony-stimulating factors in cancer patients after chemotherapy: A systematic review and Bayesian network meta-analysis. Scientific Reports 9:1.
Crossref
Crossref
Kentaro Yamao, Mamoru Takenaka, Tomoe Yoshikawa, Rei Ishikawa, Ayana Okamoto, Tomohiro Yamazaki, Atsushi Nakai, Shunsuke Omoto, Ken Kamata, Kosuke Minaga, Satoru Hagiwara, Toshiharu Sakurai, Naoshi Nishida, Yasutaka Chiba, Tomohiro Watanabe & Masatoshi Kudo. (2019) Clinical Safety and Efficacy of Secondary Prophylactic Pegylated G-CSF in Advanced Pancreatic Cancer Patients Treated with mFOLFIRINOX: A Single-center Retrospective Study. Internal Medicine 58:14, pages 1993-2002.
Crossref
Crossref
Qixiang Ye, Hebi Jiang & Hua Jiang. (2018) A comparison of the effect of xinruibai versus filgrastim on hematopoietic reconstruction after allogeneic hematopoietic stem cell transplantation. Italian Journal of Pediatrics 44:1.
Crossref
Crossref
Paul Cornes, Pere Gascon, Stephen Chan, Khalid Hameed, Catherine R. Mitchell, Polly Field, Mark Latymer & Luiz H. ArantesJr.Jr.. (2018) Systematic Review and Meta-analysis of Short- versus Long-Acting Granulocyte Colony-Stimulating Factors for Reduction of Chemotherapy-Induced Febrile Neutropenia. Advances in Therapy 35:11, pages 1816-1829.
Crossref
Crossref
T Christopher Bond, Erika Szabo, Susan Gabriel, Jean Klastersky, Omar Tomey, Udo Mueller, Lee Schwartzberg & Boxiong Tang. (2017) Meta-analysis and indirect treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related events. Journal of Oncology Pharmacy Practice 24:6, pages 412-423.
Crossref
Crossref
Matti Aapro, Ralph Boccia, Robert Leonard, Carlos Camps, Mario Campone, Sylvain Choquet, Marco Danova, John Glaspy, Iwona Hus, Hartmut Link, Thamer Sliwa, Hans Tesch & Vicente Valero. (2017) Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations. Supportive Care in Cancer 25:11, pages 3295-3304.
Crossref
Crossref
Eun-Ji ChoiJung Yong HongDok Hyun YoonJihoon KangChan-Sik ParkJooryung HuhEun Jin ChaeYoonse LeeJin-Sook RyuCheolwon Suh. (2017) Treatment outcomes of dose-attenuated CHOP chemotherapy in elderly patients with peripheral T cell lymphoma. Blood Research 52:4, pages 270.
Crossref
Crossref
Kohmei Kubo, Yasuhiko Miyazaki, Tohru Murayama, Ryutaro Shimazaki, Noriko Usui, Akio Urabe, Tomomitsu Hotta & Kazuo Tamura. (2016)
A randomized, double‐blind trial of pegfilgrastim versus filgrastim for the management of neutropenia during
CHASE
(R) chemotherapy for malignant lymphoma
. British Journal of Haematology 174:4, pages 563-570.
Crossref
Crossref
Prajna Mishra, Bismita Nayak & R.K. Dey. (2016) PEGylation in anti-cancer therapy: An overview. Asian Journal of Pharmaceutical Sciences 11:3, pages 337-348.
Crossref
Crossref
Xianglin L. Du, Yefei Zhang & Dale Hardy. (2016) Temporal and Geographic Variations in the Receipt of Colony-Stimulating Factors and Erythropoiesis-Stimulating Agents in a Large Retrospective Cohort of Older Women With Breast Cancer From 2000 to 2009. American Journal of Therapeutics 23:2, pages e411-e421.
Crossref
Crossref
H. Xu, Q. Gong, F. D. Vogl, M. Reiner & J. H. Page. (2015) Risk factors for bone pain among patients with cancer receiving myelosuppressive chemotherapy and pegfilgrastim. Supportive Care in Cancer 24:2, pages 723-730.
Crossref
Crossref
Li Wang, Onur Baser, Lucie Kutikova, John H. Page & Richard Barron. (2015) The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials. Supportive Care in Cancer 23:11, pages 3131-3140.
Crossref
Crossref
Edgar Petru, Christian F. Singer, Stephan Polterauer, Arik Galid, Christian Schauer, Johann Klocker, Michael Seifert, Alexander Reinthaller, Christoph Benedicic, Michael Hubalek, Lukas Hefler, Christian Marth, Tonja Scholl-Firon, Gerhard Bogner & Alain-Gustave Zeimet. (2015) Prophylactic long-acting granulocyte-colony stimulating factors (G-CSF) in gynecologic malignancies: an oncologic expert statementProphylaxe mit langwirksamen Granulozyten-Kolonie-stimulierenden Faktoren (G-CSF) bei gynäkologischen Malignomen. Wiener Medizinische Wochenschrift 165:19-20, pages 387-394.
Crossref
Crossref
Valentina Bozzoli, Maria C. Tisi, Elena Maiolo, Eleonora Alma, Silvia Bellesi, Francesco D'Alo’, Maria T. Voso, Giuseppe Leone & Stefan Hohaus. (2015)
Four doses of unpegylated
versus
one dose of pegylated filgrastim as supportive therapy in R-CHOP-14 for elderly patients with diffuse large B-cell lymphoma
. British Journal of Haematology 169:6, pages 787-794.
Crossref
Crossref
Tara Arvedson, James O’Kelly & Bing-Bing Yang. (2015) Design Rationale and Development Approach for Pegfilgrastim as a Long-Acting Granulocyte Colony-Stimulating Factor. BioDrugs 29:3, pages 185-198.
Crossref
Crossref
M G Kim, N Han, E-K Lee & T Kim. (2015) Pegfilgrastim vs filgrastim in PBSC mobilization for autologous hematopoietic SCT: a systematic review and meta-analysis. Bone Marrow Transplantation 50:4, pages 523-530.
Crossref
Crossref
Grace Kam, Richard Yiu, Yvonne Loh, Ai Leen Ang, Ling Ling Yueh, Yeow Tee Goh & Gee Chuan Wong. (2014) Impact of pegylated filgrastim in comparison to filgrastim for patients with acute myeloid leukaemia (AML) on high-dose cytarabine (HIDAC) consolidation chemotherapy. Supportive Care in Cancer 23:3, pages 643-649.
Crossref
Crossref
Lodovico Balducci, May Mo, Esteban Abella & Alan Saven. (2014) Retrospective Analysis of Relative Dose Intensity in Patients With Non-Hodgkin Lymphoma Receiving CHOP-based Chemotherapy and Pegfilgrastim. American Journal of Clinical Oncology 37:6, pages 603-610.
Crossref
Crossref
J.J. Vehreschild, A. Böhme, O.A. Cornely, C. Kahl, M. Karthaus, K.-A. Kreuzer, G. Maschmeyer, S. Mousset, V. Ossendorf, O. Penack, M.J.G.T. Vehreschild & J. Bohlius. (2014) Prophylaxis of infectious complications with colony-stimulating factors in adult cancer patients undergoing chemotherapy—evidence-based guidelines from the Infectious Diseases Working Party AGIHO of the German Society for Haematology and Medical Oncology (DGHO). Annals of Oncology 25:9, pages 1709-1718.
Crossref
Crossref
T. A. Khan & A. K. Gohel. (2014) PEGYLATION: CONCEPT AND APPLICATIONS IN CANCER THERAPEUTICS. INDIAN DRUGS 51:04, pages 5-19.
Crossref
Crossref
Matteo Lambertini, Lucia Del Mastro, Andrea Bellodi & Paolo Pronzato. (2014) The five “Ws” for bone pain due to the administration of granulocyte-colony stimulating factors (G-CSFs). Critical Reviews in Oncology/Hematology 89:1, pages 112-128.
Crossref
Crossref
Arash Naeim, Henry J Henk, Laura Becker, Victoria Chia, Sejal Badre, Xiaoyan Li & Robert Deeter. (2013) Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF). BMC Cancer 13:1.
Crossref
Crossref
S. Zeynalova, M. Ziepert, M. Scholz, S. Schirm, C. Zwick, M. Pfreundschuh & M. Loeffler. (2013) Comparison and modelling of pegylated or unpegylated G-CSF schedules in CHOP-14 regimen of elderly patients with aggressive B-cell lymphoma. Annals of Hematology 92:12, pages 1641-1652.
Crossref
Crossref
L. Jolis, F. Carabantes, S. Pernas, B. Cantos, A. López, P. Torres, C. Funes, D. Caballero, P. Benedit & A. Salar. (2013) Incidence of chemotherapy-induced neutropenia and current practice of prophylaxis with granulocyte colony-stimulating factors in cancer patients in Spain: a prospective, observational study. European Journal of Cancer Care 22:4, pages 513-521.
Crossref
Crossref
Yuan-Kai Shi, Qiang Chen, Yun-Zhong Zhu, Xiao-Hui He, Hua-Qing Wang, Ze-Fei Jiang, Jian Hua Chang, Yun-Peng Liu, An-Lan Wang, De-Yun Luo, Yang Zhang, Xiao-Yan Ke, Wei-Lian Li, Wei-Jing Zhang, Xiu-Wen Wang, Yi-Ping Zhang, Jian-Min Wang & Xiao-Qing Liu. (2013) Pegylated filgrastim is comparable with filgrastim as support for commonly used chemotherapy regimens. Anti-Cancer Drugs 24:6, pages 641-647.
Crossref
Crossref
D. Almenar Cubells, C. Bosch Roig, E. Jiménez Orozco, R. Álvarez, J.M. Cuervo, N. Díaz Fernández, A.B. Sánchez Heras, A. Galán Brotons, V. Giner Marco & M. Codes M. De Villena. (2013) Effectiveness of daily versus non‐daily granulocyte colony‐stimulating factors in patients with solid tumours undergoing chemotherapy: a multivariate analysis of data from current practice. European Journal of Cancer Care 22:3, pages 400-412.
Crossref
Crossref
Justyna Dzietczenia. (2013) Profilaktyka neutropenii u pacjentów w wieku podeszłym. Acta Haematologica Polonica 44:2, pages 124-129.
Crossref
Crossref
Markus Scholz, Sibylle Schirm, Marcus Wetzler, Christoph Engel & Markus Loeffler. (2012) Pharmacokinetic and -dynamic modelling of G-CSF derivatives in humans. Theoretical Biology and Medical Modelling 9:1.
Crossref
Crossref
Katy L Cooper, Jason Madan, Sophie Whyte, Matt D Stevenson & Ron L Akehurst. (2011) Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer 11:1.
Crossref
Crossref
R Pettengell, M Schwenkglenks, P Bacon, S Lawrinson & U Duehrsen. (2011) Pegfilgrastim primary prophylaxis in patients with non‐Hodgkin lymphoma: results from an integrated analysis. Hematological Oncology 29:4, pages 177-184.
Crossref
Crossref
Hong Zhao, Lee M. Greenberger & Ivan D. Horak. 2011. Drug Delivery in Oncology. Drug Delivery in Oncology
627
665
.
Jason Madan, Matt D. Stevenson, Katy L. Cooper, A.E. Ades, Sophie Whyte & Ron Akehurst. (2011) Consistency between Direct and Indirect Trial Evidence: Is Direct Evidence Always More Reliable?. Value in Health 14:6, pages 953-960.
Crossref
Crossref
Stephanie A. Gregory, Steve Abella & Tim Moore. (2011) Underreporting of neutropenic toxicity associated with current treatment regimens for selected hematologic malignancies. Community Oncology 8:7, pages 311-325.
Crossref
Crossref
Sophie Whyte, Katy L. Cooper, Matt D. Stevenson, Jason Madan & Ron Akehurst. (2011) Cost-Effectiveness of Granulocyte Colony–Stimulating Factor Prophylaxis for Febrile Neutropenia in Breast Cancer in the United Kingdom. Value in Health 14:4, pages 465-474.
Crossref
Crossref
Jean Klastersky & Ahmad Awada. (2011) Prevention of febrile neutropenia in chemotherapy-treated cancer patients: Pegylated versus standard myeloid colony stimulating factors. Do we have a choice?. Critical Reviews in Oncology/Hematology 78:1, pages 17-23.
Crossref
Crossref
Alexandre CHAN, Xue Zhen LENG, Joen YL CHIANG, Miriam TAO, Richard QUEK, Kevin TAY & Soon Thye LIM. (2011) Comparison of daily filgrastim and pegfilgrastim to prevent febrile neutropenia in Asian lymphoma patients. Asia-Pacific Journal of Clinical Oncology 7:1, pages 75-81.
Crossref
Crossref
M.S. Aapro, J. Bohlius, D.A. Cameron, Lissandra Dal Lago, J. Peter Donnelly, N. Kearney, G.H. Lyman, R. Pettengell, V.C. Tjan-Heijnen, J. Walewski, Damien C. Weber & C. Zielinski. (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. European Journal of Cancer 47:1, pages 8-32.
Crossref
Crossref
Stephanie A. Gregory, Lee S. Schwartzberg, May Mo, Jorge Sierra & Charles Vogel. (2010) Evaluation of reported bone pain in cancer patients receiving chemotherapy in pegf lgrastim clinical trials: a retrospective analysis. Community Oncology 7:7, pages 297-308.
Crossref
Crossref
F.M. Veronese, G. Pasut, S. Drioli & G.M. Bonora. 2010. Macromolecular Anticancer Therapeutics. Macromolecular Anticancer Therapeutics
265
288
.
M. Scholz, C. Engel, D. Apt, S. L. Sankar, E. Goldstein & M. Loeffler. (2009) Pharmacokinetic and pharmacodynamic modelling of the novel human granulocyte colony-stimulating factor derivative Maxy-G34 and pegfilgrastim in rats. Cell Proliferation 42:6, pages 823-837.
Crossref
Crossref
M. Scholz, M. Ackermann, C. Engel, F. Emmrich, M. Loeffler & M. Kamprad. (2009) A pharmacokinetic model of filgrastim and pegfilgrastim application in normal mice and those with cyclophosphamide-induced granulocytopaenia. Cell Proliferation 42:6, pages 813-822.
Crossref
Crossref
Gianfranco Pasut & Francesco M. Veronese. (2009) PEG conjugates in clinical development or use as anticancer agents: An overview. Advanced Drug Delivery Reviews 61:13, pages 1177-1188.
Crossref
Crossref
Ruth Pettengell, Matti Aapro, Ercole Brusamolino, Dolores Caballero, Bertrand Coiffier, Michael Pfreundschuh, Marek Trneny & Jan Walewski. (2009) Implications of the European Organisation for Research And Treatment Of Cancer (EORTC) Guidelines on the Use of Granulocyte Colony-Stimulating Factor (G-CSF) for Lymphoma Care. Clinical Drug Investigation 29:8, pages 491-513.
Crossref
Crossref
N. Yamamoto, I. Sekine, K. Nakagawa, M. Takada, M. Fukuoka, Y. Tanigawara & N. Saijo. (2009) A Pharmacokinetic and Dose Escalation Study of Pegfilgrastim (KRN125) in Lung Cancer Patients with Chemotherapy-induced Neutropenia. Japanese Journal of Clinical Oncology 39:7, pages 425-430.
Crossref
Crossref
William Renwick, Ruth Pettengell & Michael Green. (2009) Use of Filgrastim and Pegfilgrastim to Support Delivery of Chemotherapy. BioDrugs 23:3, pages 175-186.
Crossref
Crossref
F Willis, P Woll, D Theti, H Jamali, P Bacon, N Baker & R Pettengell. (2009) Pegfilgrastim for peripheral CD34+ mobilization in patients with solid tumours. Bone Marrow Transplantation 43:12, pages 927-934.
Crossref
Crossref
Derek Weycker, Jennifer Malin, John Kim, Rich Barron, John Edelsberg, Alex Kartashov & Gerry Oster. (2009) Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: A retrospective cohort study. Clinical Therapeutics 31:5, pages 1069-1081.
Crossref
Crossref
Patrizia Zappasodi, Anna Maria Nosari, Cesare Astori, Dennis Ciapanna, Maurizio Bonfichi, Marzia Varettoni, Silvia Mangiacavalli, Enrica Morra, Mario Lazzarino & Alessandro Corso. (2008) DCEP chemotherapy followed by a single, fixed dose of pegylated filgrastim allows adequate stem cell mobilization in multiple myeloma patients. Transfusion 48:5, pages 857-860.
Crossref
Crossref
Bing‐Bing Yang, Anna Kido & Atsuko Shibata. (2012) Serum Pegfilgrastim Concentrations During Recovery of Absolute Neutrophil Count in Patients with Cancer Receiving Pegfilgrastim After Chemotherapy. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 27:10, pages 1387-1393.
Crossref
Crossref
Tjakiena Henriette Levenga & Johanna N. H. Timmer‐Bonte. (2007) Review of the value of colony stimulating factors for prophylaxis of febrile neutropenic episodes in adult patients treated for haematological malignancies. British Journal of Haematology 138:2, pages 146-152.
Crossref
Crossref
Nila Bhana. (2007) Granulocyte colony-stimulating factors in the management of chemotherapy-induced neutropenia: evidence based review. Current Opinion in Oncology 19:4, pages 328-335.
Crossref
Crossref
Ulrich J. M. Mey, Anna Maier, Ingo G. H. Schmidt-Wolf, Carsten Ziske, Helmut Forstbauer, Gamal-Andre Banat, Michael Reber, John W. Strehl & Marcus Gorschlueter. (2007) Pegfilgrastim as hematopoietic support for dose-dense chemoimmunotherapy with R-CHOP-14 as first-line therapy in elderly patients with diffuse large B cell lymphoma. Supportive Care in Cancer 15:7, pages 877-884.
Crossref
Crossref
Riccardo RicottaGiulio CereaIlaria SchiavettoMaria Rosaria MaugeriPaolo PedrazzoliSalvatore Siena. (2006) Pegfilgrastim: current and future perspectives in the treatment of chemotherapy-induced neutropenia. Future Oncology 2:6, pages 667-676.
Crossref
Crossref
M.S. Aapro, D.A. Cameron, R. Pettengell, J. Bohlius, J. Crawford, M. Ellis, N. Kearney, G.H. Lyman, V.C. Tjan-Heijnen, J. Walewski, D.C. Weber & C. Zielinski. (2006) EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. European Journal of Cancer 42:15, pages 2433-2453.
Crossref
Crossref
R. Pirker, E. Ulsperger, J. Messner, K. Aigner, B. Forstner, P. Bacon, V. Easton & T. Skacel. (2006) Achieving Full-Dose, On-Schedule Administration of ACE Chemotherapy Every 14 Days for the Treatment of Patients with Extensive Small-Cell Lung Cancer. Lung 184:5, pages 279-285.
Crossref
Crossref
A Nosari, R Cairoli, D Ciapanna, L Gargantini, L Intropido, C Baraté, B Scarpati, L Santoleri, G Nador, L Pezzetti & E Morra. (2006) Efficacy of single dose pegfilgrastim in enhancing the mobilization of CD34+ peripheral blood stem cells in aggressive lymphoma patients treated with cisplatin-aracytin-containing regimens. Bone Marrow Transplantation 38:6, pages 413-416.
Crossref
Crossref
Ingmar Bruns, Ulrich Steidl, Ralf Kronenwett, Roland Fenk, Thorsten Graef, Ulrich-Peter Rohr, Frank Neumann, Johannes Fischer, Christof Scheid, Kai Hübel, Rainer Haas & Guido Kobbe. (2006) A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma. Transfusion 46:2, pages 180-185.
Crossref
Crossref
Janice L. Gabrilove. (2006) An analysis of current neutropenia therapies, including pegfilgrastim. Clinical Cornerstone 8, pages S19-S28.
Crossref
Crossref
Diana Lüftner & Kurt Possinger. (2005) Pegfilgrastim – Rational Drug Design for the Management of Chemotherapy-Induced Neutropenia. Oncology Research and Treatment 28:11, pages 595-602.
Crossref
Crossref
U Steidl, R Fenk, I Bruns, F Neumann, M Kondakci, B Hoyer, T Gräf, U-P Rohr, S Bork, R Kronenwett, R Haas & G Kobbe. (2004) Successful transplantation of peripheral blood stem cells mobilized by chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. Bone Marrow Transplantation 35:1, pages 33-36.
Crossref
Crossref
K. Possinger, A. Schauer, F. Griesinger & A. C. Roever. 2005. The Sentinel Lymph Node Concept. The Sentinel Lymph Node Concept
503
551
.
A.-R. WALADKHANI. (2004) Pegfilgrastim: a recent advance in the prophylaxis of chemotherapy-induced neutropenia. European Journal of Cancer Care 13:4, pages 371-379.
Crossref
Crossref
. (2004) Current Awareness in Hematological Oncology. Hematological Oncology 22:1, pages 35-42.
Crossref
Crossref